Lee Greenberger, PhD, chief scientific officer, The Leukemia & Lymphoma Society, discusses how the society contributes to blood cancer research.
Lee Greenberger, PhD, chief scientific officer, The Leukemia & Lymphoma Society, discusses how the society contributes to blood cancer research.
The Leukemia & Lymphoma Society recently passed the $1 billion mark in research investment, Greenberger said. The society currently has 320 active programs available.
The journey from a laboratory discovery to a therapy that can control disease takes about 10 years. Sustained funding is needed in order to make progress in this field, Greenberger says, and the society’s volunteers, advocates, and cancer patients step up in order to make progress in the field happen.
To learn more about The Leukemia & Lymphoma Society, visit www.lls.org.
Survival Benefit, Durable Responses Continue at 3 Years With Liso-cel in Second-line LBCL
July 15th 2024Three-year findings from the TRANSFORM trial provide further evidence that liso-cel should be considered as the new standard of care along with other CAR T-cell therapies for patients with primary refractory or relapsed LBCL, an expert said.